For informational purposes only — not investment advice

← Back to signals

UNH

SHORTINSIDER SELLCONGRESS BUYCONGRESS SELL

UNITEDHEALTH GROUP INC

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.

Funds
3
Score
2.37
vs SPY
+29.6%
Stock return (since Q-end)
+49.3%
SPY return (since Q-end)
+19.7%
Current price
$401.73
Days to cover (short int.)
2.5d-13.0%
as of 2026-07-31

News Summary

Neutral

UnitedHealth delivered strong operational execution in H1 2026 with significant earnings beats and multiple guidance raises, driven by improved medical cost management and favorable reserve releases. However, the company faces material headwinds from DOJ criminal and civil investigations into Medicare Advantage billing practices, membership declines from affordability pressures, and expanded antitrust scrutiny of its Claritev unit.

Red flags

  • DOJ criminal investigation into Medicare Advantage billing practices and diagnosis inflation allegations
  • DOJ expanded antitrust investigation into Claritev unit with new civil investigative demands alleging collusion
  • Membership declines: 525,000 loss in Q2 alone; guidance for 500,000 ACA and 1.1M Medicare Advantage losses in 2026
  • Regulatory pressure from proposed flat Medicare Advantage payment increases and federal transparency rules on PBM operations
  • Material reliance on prior-period reserve releases ($860M in Q2) to drive earnings recovery, raising sustainability concerns

Funds Reducing / Exiting (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Appaloosa LPDavid Tepper90K-110,000$24M1.0%-55%Existing
Viking GlobalAndreas Halvorsen0−1.2M1.0%-100%EXITED
Berkshire HathawayWarren Buffett0−5.0M0.6%-100%EXITED

Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Conway Patrick HughChief Executive Officer, OptumSELL500$410.00$0.20M2026-08-05
Conway Patrick HughChief Executive Officer, OptumSELL800$355.00$0.28M2026-04-23

Congressional Trading

MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Maria Elvira SalazarhouseFL27SELL$1,001 - $15,0002026-06-042026-07-07
John BoozmansenateBUY$1,001 - $15,0002026-06-042026-07-13
Alan ArmstrongsenateBUY$15,001 - $50,0002026-03-272026-07-21

Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures.